Sirona Biochem: The Leader in Carbohydrate Stabilization Technology

Sirona Biochem: The Global Leader in Carbohydrate Stabilization Technology

– Momentum Public Relations –


Sirona Biochem (SBM:tsxv) is a proactive development and discovery stage based biotech firm with an R&D lab situated in Paris, France. The biotechnology enterprise is headquartered in Vancouver, British Columbia in Canada, and is world renowned for its state of the art fluorination chemistry technology. Thtf chem labeir cutting edge platform is currently used to create cosmetic products that are both safe and effective for human use and consumption, as well as a plethora of pharmaceutical drugs.

Moreover, their leading edge compounds are either acquired by or licensed by multinational conglomerates in return for royalties, milestone payments, and/or marked upfront payments. It should also be noted that their platform focuses on the molecular stabilization of carbohydrates; which is noteworthy because carbohydrate based drugs are one of the most commonly prescribed drug families in the United States. De facto, some of the most commonly prescribed carbohydrate based drugs in the United States include Abbott’s Biaxin, Pfizer’s Zithromax, and GlaxoSmithKline’s Lanoxin.

In addition, Sirona Biochem currently has two licensing agreements with two multibillion dollar companies; namely Valeant Pharmaceuticals International (VRX:tsx) and Wanbang Biopharma. Valeant was founded in 1960 in Laval, Quebec, Canada and generated revenues of 2.73 billion U.S. in Q2 of 2015. What’s more, Valeant recently licensed a safe and innovative skin lightener, with Sirona Biochem to reap several millions in royalties in the near future from the licensing deal.

As for Wanbang Biopharma, the company was founded in China in 1998 and is a part of Fosun International (9.4 billion in U.S. revenue). The corporation focuses on the development of pharmaceutical drugs used to treat diabetes and associated cardiovascular diseases. Wanbang Biopharma also recently acquired the exclusive rights to sell the SGLT2 inhibitor that Sirona Biochem developed to treat type 2 diabetes. With the exclusive rights, Wanbang Biopharma will be able to sell the inhibitor in the People’s Republic of China, with $9.5 million in U.S. payments being awarded to Sirona Biochem in the form of milestone and upfront payments; with a percentage of total sales also being awarded to the pharmaceutical company in the form of perpetual royalties.

In regards to the skin lightening market, it is currently focused in the Asian Pacific regions and Japan, with the booming market expected to generate ovsirona-girler 20 billion U.S. in revenue by 2018; with an annual growth rate projected at 25%. However, many of the skin lightening products currently being sold globally contain malevolent compounds; including DeoxyArbutin, Arbutin, and Hydroquinone. Due to the controversy and health concerns surrounding the aforementioned skin lightener compounds products containing these compounds are strictly regulated and even outright banned in certain countries.

Fortunately, Sirona Biochem has created a safe alternative compound known as TFC-1067 to resolve these issues. TFC-1067 is not only safe but also boasts 8 times the efficacy of DeoxyArbutin. Given the numerous benefits that TFC-1067 provides over its competitors, multinational cosmetic conglomerates like Proctor and Gamble, Allergan, L’Oreal, and Amore Pacific Corporation with marketed skin lighteners are interested in Sirona’s leading edge compound.

Industry analysts have predicted that the global anti-aging market is expected to reach nearly $300 billion by 2015.  Interestingly, Sirona is developing unique regenerative compounds based on research conducted by Professor Arthur DeVrie in the late 1960s. Essentially, his research found that the reason why Antarctic fish were able to survive in harsh, subzero temperatures was due to blood serum glycoproteins. Inspired by Professor Arthur DeVrie’s monumental discovery, Sirona Biochem is currently producing a family of regenerative, anti-aging, and naturally occurring compounds that are based on the antifreeze and anti-aging glycoproteins

Furthermore, in vitro studies have shown that these glycoproteins have a protective effect in fibroblasts against a myriad of stresses caused by nutrient depravation, oxidation, and UV light; all of which contribute to the visible signs of aging.

As Sirona Biochem continues to work diligently to harness the full protective and restorative properties of these glycoproteins the company is currently looking to collaborate with several global multinationals to further characterize and develop these glycoproteins for a myriad of commercial applications. In addition, their early stage partnerships with many prominent entities will allow Sirona Biochem to provide added value to their shareholders by maximizing their ROI. Another benefit of their ongoing projects is that they have a very short time to approval; with FDA approvals not being required.

sirona-lab

If you would like to learn more about the world leader in carbohydrate chemistry commercialization please visit here.

2 Comments
  1. I needs to spend some time learning much more or understanding more. Thanks for great info I was looking for this info for my mission.

  2. Way cool! Some very valid points! I appreciate you penning this article and also the rest of the site is really good.

Leave a Reply

Please wait...

Knowledge is Power

Knowledge is a necessity for all savvy investors. To achieve great CONSISTENT returns, smart investors know they need all the information they can get. We have your information!